Fig. 2
PL prominently improves TMZ and surgery/TMZ efficacy in G422TN-mice. A Schematic diagram depicting the Piperlongumine (PL), TMZ chemotherapy (TMZ), or their combined regimen started on day 7 p.i. PL, 10 doses of PL with once oral gavage of 5 µg/g. B and C The Kaplan-Meier survivals and body weight changes of the G422TN-mice with PL, TMZ, or TMZ/PL treatment started on day 7 p.i. (n = 8/group). D and E Representative bioluminescent images and statistical analysis of the ROI values of the intracranial tumors monitored on day 18 p.i. (n = 8/group). F Schematic diagram of the surgery, PL, TMZ chemotherapy (TMZ), or their combined regimen started on day 7–8 p.i.G and H The Kaplan-Meier survivals and body weight changes of the G422TN-mice with surgery, PL, TMZ, or their combined regimen started on day 7–8 p.i. (n = 8–10/group). (*P < 0.05; **P < 0.01; ****P < 0.0001)